Chiral hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: the search for selective p53-activating agents for colorectal cancer therapy-Reference-Cited by-同舟云学术

Chiral hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: the search for selective p53-activating agents for colorectal cancer therapy

Published:2024 Issue:5 Volume:15 Page:1652-1663
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Hendrikx Mees M.¹,Pereira Adelino M. R.¹^ORCID,Pereira Ana B.¹,Carvalho Carla S. C.²,Ribeiro João L. P.¹^ORCID,Soares Maria I. L.¹^ORCID,Saraiva Lucília²^ORCID,Pinho e Melo Teresa M. V. D.¹^ORCID

Affiliation:

1. University of Coimbra, Coimbra Chemistry Centre – Institute of Molecular Sciences and Department of Chemistry, 3004-535 Coimbra, Portugal

2. LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal

Abstract

Structural modulation of a lead p53-activating anticancer molecule was performed, leading to the synthesis of new bioactive molecules. Activity against human colorectal cancer cells with different p53 status provided in-depth SAR data.

Funder

Fundação para a Ciência e a Tecnologia

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00076E

Reference20 articles.

1. Global cancer control: responding to the growing burden, rising costs and inequalities in access

2. WHO report on cancer: setting priorities, investing wisely and providing care for all , World Health Organization , Geneva , 2020

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. Colorectal cancer

5. A selective p53 activator and anticancer agent to improve colorectal cancer therapy